Healthcare of Ontario Pension Plan Trust Fund Has $5.57 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 127.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 83,037 shares of the medical device company’s stock after acquiring an additional 46,527 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in DexCom were worth $5,567,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom during the second quarter worth approximately $25,000. Sachetta LLC boosted its holdings in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. DT Investment Partners LLC grew its position in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares during the period. Riverview Trust Co increased its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. Finally, ORG Partners LLC lifted its position in shares of DexCom by 1,992.0% during the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock valued at $59,000 after acquiring an additional 498 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on DXCM. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Robert W. Baird raised their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Finally, Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Trading Down 0.1 %

NASDAQ:DXCM opened at $77.99 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm has a 50-day moving average price of $71.39 and a two-hundred day moving average price of $88.11. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market cap of $30.46 billion, a price-to-earnings ratio of 46.70, a price-to-earnings-growth ratio of 2.39 and a beta of 1.17.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.